Esophageal cancer natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
Complications of esophageal cancer include dysphagia, anemia, and tracheoesophageal fistula. Esophageal cancer is associated with a 5 year survival rate of 20%.
Complications of esophageal cancer include dysphagia, anemia, and tracheoesophageal fistula. The incidence of esophageal dysplasia turning malignant is very low, especially outside the United States. This finding has caused some uncertainty as to the usefulness of screening. Esophageal cancer is associated with a 5 year survival rate of 20%.


==Natural history==
==Natural history==
*From May 2012 to February 2014, 2093 patients were screened endoscopically to record the natural history of esophageal cancer, from dysplasia to cancer.
*In total, 39 were diagnosed with severe dysplasia.
*Of the 39 severe dysplasia cases diagnosed by endoscopy, only 8 progressed to carcinoma with a mean time of 33.8 months and a median time of 30 months.
*Excessively frequent endoscopy follow-up was found to waste medical resources and also lowered the compliance, while long, overdue follow-up intervals may cause unacceptable disease progression.
*The study concluded that severe dysplasia cases may have much lower carcinoma progression rate than other dysplasia due to some cases remaining stable or due to the phenomenon of dysplasia reversal.
==Complications==
==Complications==
Complications can occur as a product of esophageal cancer or because of radiotherapeutic treatment.
Complications can occur as a product of esophageal cancer or because of radiotherapeutic treatment.

Revision as of 16:54, 11 December 2017

Esophageal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Esophageal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esophageal cancer natural history, complications and prognosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esophageal cancer natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esophageal cancer natural history, complications and prognosis

CDC on Esophageal cancer natural history, complications and prognosis

Esophageal cancer natural history, complications and prognosis in the news

Blogs on Esophageal cancer natural history, complications and prognosis

Directions to Hospitals Treating Esophageal cancer

Risk calculators and risk factors for Esophageal cancer natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: mHadeel Maksoud M.D.[2]

Overview

Complications of esophageal cancer include dysphagia, anemia, and tracheoesophageal fistula. The incidence of esophageal dysplasia turning malignant is very low, especially outside the United States. This finding has caused some uncertainty as to the usefulness of screening. Esophageal cancer is associated with a 5 year survival rate of 20%.

Natural history

  • From May 2012 to February 2014, 2093 patients were screened endoscopically to record the natural history of esophageal cancer, from dysplasia to cancer.
  • In total, 39 were diagnosed with severe dysplasia.
  • Of the 39 severe dysplasia cases diagnosed by endoscopy, only 8 progressed to carcinoma with a mean time of 33.8 months and a median time of 30 months.
  • Excessively frequent endoscopy follow-up was found to waste medical resources and also lowered the compliance, while long, overdue follow-up intervals may cause unacceptable disease progression.
  • The study concluded that severe dysplasia cases may have much lower carcinoma progression rate than other dysplasia due to some cases remaining stable or due to the phenomenon of dysplasia reversal.

Complications

Complications can occur as a product of esophageal cancer or because of radiotherapeutic treatment.

Complications due to esophageal cancer

  • Anemia
  • Weight loss
  • Dysphagia
  • Cachexia
  • Aspiration pneumonia
  • Metastases

Complications of radiotherapy

  • Tracheoesophageal fistula
  • Postradiotherapy esophageal strictures, may lead to recurrent dysphagia.[1]

Prognosis

5-Year Survival

  • Between 2004 and 2010, the 5-year relative survival of patients with esophageal cancer was 20 %.[2]
  • When stratified by age, the 5-year relative survival of patients with esophageal cancer was 19.8 % and 15.5 % for patients <65 and ≥ 65 years of age respectively.[2]
  • The survival of patients with esophageal cancer varies with the stage of the disease.
  • Shown below is a table depicting the 5-year relative survival by the stage of esophageal cancer:[2]
Stage 5-year relative survival (%), (2004-2010)
All stages 17.5%
Localized 39.6%
Regional 21.1%
Distant 3.8%
Unstaged 11.5%

Shown below is an image depicting the 5-year conditional relative survival (probability of surviving in the next 5-years) between 1998 and 2010 of esophageal cancer by stage at diagnosis according to SEER. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[2]

<figure-inline class="mw-default-size"><figure-inline></figure-inline></figure-inline>

References

  1. O'Rourke IC, Tiver K, Bull C, Gebski V, Langlands AO (1988). "Swallowing performance after radiation therapy for carcinoma of the esophagus". Cancer. 61 (10): 2022–6. PMID 2452006.
  2. 2.0 2.1 2.2 2.3 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.


Template:WikiDoc Sources